Home
NewsNewsCDSCO Orders on IVF Medical Devices reinforce strict regulatory oversight across India’s fertility sector. The directive mandates licensing compliance under existing laws, ensuring IVF and ART devices meet safety and quality standards. This move aims to curb unauthorized sales, strengthen enforcement, and bring greater accountability to medical device usage in reproductive healthcare.
Through a recent notice, the Central Drugs Standard Control Organization (CDSCO) has directed strict regulatory oversight on the import, manufacture, sale, and distribution of medical devices used in In Vitro Fertilization (IVF) and Assisted Reproductive Technology (ART) procedures. This move, highlighted under CDSCO Orders on IVF Medical Devices, reinforces the need for compliance across the sector.
The directive highlights that all medical devices are regulated under the provisions of the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017, and require appropriate licensing for import, manufacturing, sale, and distribution, except for Class A non-sterile and non-measuring medical devices. Under the CDSCO Orders on IVF Medical Devices, adherence to these frameworks has been strongly reiterated.
It further clarifies that devices used in IVF procedures, including IUI (Intrauterine Insemination) kits and centrifuges for sperm washing, fall within the definition of medical devices under the existing regulatory framework. The CDSCO has taken note of instances where firms are selling medical devices intended for In Vitro Fertilization viz., IUI (Intrauterine Insemination) kits, centrifuges for sperm washing, etc., used for Assisted Reproductive Technology related procedures without obtaining a licence from the licensing authority under the Medical Devices Rules, 2017.
In response, the apex drug regulator has instructed all State and Union Territory drug control and licensing authorities to maintain strict vigilance and ensure that no such devices are imported, manufactured, distributed, or sold without compliance with the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017. This enforcement push forms a critical part of the ongoing CDSCO Orders on IVF Medical Devices.
The notice concluded by directing all State/UT Drugs Control and Licensing Authorities, Zonal, Sub-Zonal and Port Offices of the Central Drugs Standard Control Organization (CDSCO), as well as stakeholders through its official website, stating: "You are requested to keep strict vigil & ensure that no such devices used for In Vitro Fertilization for Assisted Reproductive Technology related procedures are being imported, manufactured, distributed, sold without bidance to the Drugs and Cosmetics Act,1940 and Medical Devices Rules, 2017."
The circular has been addressed to all State/UT Drugs Control and Licensing Authorities, along with all Zonal, Sub-Zonal, and Port Offices of CDSCO. It has also been shared with stakeholders via the CDSCO website for wider awareness and compliance.
The Tennessee State Law could change how the embryos are handled at the time of treatment, thereby making the IVF clinic services in the state more expensive for patients seeking fertility care.
Before taking a call on IVF, survey conducted in the U.S., UK, Ireland, and Canada suggests that people are looking for complete & less expensive options to treat root causes of infertility.
Technology-Enabled Cryostorage is transforming fertility storage as Reprotech and TMRW combine expertise in digital specimen management and biorepository services. The partnership enhances scalability, safety, and efficiency while supporting clinics with advanced solutions. This strategic move positions the combined company to lead innovation and meet growing global demand in cryostorage services.
First AI-powered egg-freezing program has been initiated by Sunfish with an intent to get rid of uncertainty within the fertility preservation space, offering personalised insights and higher success predictability for women.
3billion has gone on to launch the Family Insight Test using WES and WGS analysis aimed at targeting couples who cannot get pregnant for no apparent reason, helping them discover hidden genetic factors affecting fertility.
Arbor Fertility™ with 8 locations in Missouri & Illinois has designed a streamlined patient-centred approach leading to Affordable, Accessible Fertility Care, making high-quality treatment available without financial burden.
